Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
98.573,43
-0,46%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acumen Pharmaceuticals Inc (ABOS) Acumen Pharmaceuticals Inc (ABOS) Notizie

Acumen Pharmaceuticals Inc

ABOS
2,40
0,09 (3,90%)
23 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/11/202422:29EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202413:00GLOBEAcumen Pharmaceuticals Reports Third Quarter 2024 Financial..
11/11/202422:00GLOBEAcumen Pharmaceuticals to Participate in the Stifel..
06/11/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/11/202423:24EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/11/202422:00GLOBEAcumen Pharmaceuticals to Participate in the UBS Global..
06/11/202414:00GLOBEAcumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief..
05/11/202422:00GLOBEAcumen Pharmaceuticals to Report Third Quarter Results on..
31/10/202413:05GLOBEAcumen Pharmaceuticals Presents Innovative Trial Screening..
23/10/202414:00GLOBEAcumen Pharmaceuticals to Deliver Late-Breaking Presentation..
30/9/202422:00GLOBEAcumen Pharmaceuticals to Participate in the Bank of America..
26/9/202414:00GLOBEAcumen Pharmaceuticals Extends Collaboration with Lonza to..
25/9/202422:00GLOBEAcumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2,..
03/9/202422:00GLOBEAcumen Pharmaceuticals to Participate in the H.C. Wainwright..
13/8/202422:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202413:48EDGAR2Form 8-K - Current report
13/8/202413:00GLOBEAcumen Pharmaceuticals Reports Second Quarter 2024 Financial..
06/8/202422:00GLOBEAcumen Pharmaceuticals to Report Second Quarter Results on..
29/7/202413:00GLOBEAcumen Pharmaceuticals Announces First Subject Dosed in..
28/7/202413:30GLOBEAcumen Pharmaceuticals Presents Patient Experience and..
10/6/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202422:36EDGAR2Form 8-K - Current report
14/5/202422:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202413:35EDGAR2Form 8-K - Current report
14/5/202413:00GLOBEAcumen Pharmaceuticals Reports First Quarter 2024 Financial..
13/5/202422:00GLOBEAcumen Pharmaceuticals to Participate in the H.C. Wainwright..
08/5/202423:47GLOBEAcumen Pharmaceuticals to Participate in the 2024 Bank of..
08/5/202414:00GLOBEAcumen Pharmaceuticals Announces First Patient Dosed in..
07/5/202422:00GLOBEAcumen Pharmaceuticals to Report First Quarter Results on..
16/4/202414:00GLOBEAcumen Pharmaceuticals Presents First Comprehensive Clinical..
04/4/202414:00GLOBEAcumen Pharmaceuticals Collaborates with Lonza to Advance..
26/3/202412:00GLOBEAcumen Pharmaceuticals Reports Financial Results for the..
21/3/202413:00GLOBEAcumen Pharmaceuticals to Present Deeper Insights, Including..
19/3/202421:00GLOBEAcumen Pharmaceuticals to Report Fourth Quarter and Year-End..
12/3/202421:00GLOBEAcumen Pharmaceuticals to Participate in the Stifel 2024 CNS..
08/3/202414:50GLOBEAcumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid..
21/2/202414:00GLOBEAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid..
14/2/202414:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202423:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/2/202413:16EDGAR2Form 8-K - Current report
01/2/202413:00GLOBEAcumen Pharmaceuticals Appoints Dr. James Doherty as..
20/1/202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202401:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 2,30 Min: 2,26 Max: 2,38
Chiusura: 2,31

La tua Cronologia

NASDAQ
ABOS
Acumen Pharmaceuticals
DOWI
DJUSCC
DJ US Commodity Chemicals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network